Prescient Therapeutics Ltd signs CAR-T agreement with Peter Mac Cancer Centre
Prescient Therapeutics signs CAR-T agreement with Peter Mac Cancer Centre The new CAR-T agreement for the OmniCAR platform adds to Prescient’s existing and related research program with Peter Mac into Cell Therapy Enhancements. OmniCAR seeks to make CAR-T more controllable and adaptable. Prescient Therapeutics Ltd (ASX:PTX) has signed an agreement related to advancing a new research program with world-renowned Peter MacCallum Cancer Centre to advance its next-generation CAR-T program utilising the OmniCAR platform. Prescient has an existing research agreement with Peter Mac focu...
Source: proactiveinvestors.com.au